CRSP - Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
2023-12-11 05:43:00 ET
Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with sickle cell disease.
The medical community cheered, but the stock market's response caught many investors off guard. Instead of shooting higher, CRISPR Therapeutics stock fell 8% on the day of its big announcement.
Is CRISPR Therapeutics a good biotech stock to buy on the recent dip? To answer that, we need to understand what its new therapy can and can't do.
For further details see:
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?